Literature DB >> 28181959

Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Taishiro Kishimoto1, Sohag Sanghani, Mark J Russ, Akeem N Marsh, Joshua Morris, Suparna Basu, Majnu John, John M Kane.   

Abstract

Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed. Of 305 charts reviewed, consisting of 279 unique patients, 27.2% were judged to have an indication for an LAI (n=76), but only 32.9% of these (n=25) were discharged on an LAI. In the multiregression model, being African American, residing in a psychiatric residence, having a previous history of an LAI trial, and being treated with a higher antipsychotic dose were predictive of LAI prescription. It is important to focus on the population who are not likely to receive an LAI, but who have such indications for treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28181959      PMCID: PMC5808869          DOI: 10.1097/YIC.0000000000000165

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  45 in total

1.  Attitudes of psychiatrists toward antipsychotic depot medication.

Authors:  Stephan Heres; Johannes Hamann; Werner Kissling; Stefan Leucht
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

2.  Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

Authors:  J M Kane; E Aguglia; A C Altamura; J L Ayuso Gutierrez; N Brunello; W W Fleischhacker; W Gaebel; J Gerlach; J D Guelfi; W Kissling; Y D Lapierre; E Lindström; J Mendlewicz; G Racagni; L S Carulla; N R Schooler
Journal:  Eur Neuropsychopharmacol       Date:  1998-02       Impact factor: 4.600

3.  Systematic review of patient and nurse attitudes to depot antipsychotic medication.

Authors:  J Walburn; R Gray; K Gournay; S Quraishi; A S David
Journal:  Br J Psychiatry       Date:  2001-10       Impact factor: 9.319

Review 4.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

5.  Antipsychotic use in Australia: the patients' perspective.

Authors:  David Castle; Vera Morgan; Assen Jablensky
Journal:  Aust N Z J Psychiatry       Date:  2002-10       Impact factor: 5.744

6.  Compliance, quality assurance and standards for relapse prevention in schizophrenia.

Authors:  W Kissling
Journal:  Acta Psychiatr Scand Suppl       Date:  1994

7.  Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.

Authors:  Lizheng Shi; Haya Ascher-Svanum; Baojin Zhu; Douglas Faries; William Montgomery; Stephen R Marder
Journal:  Psychiatr Serv       Date:  2007-04       Impact factor: 3.084

8.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors:  Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

9.  The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.

Authors:  Matthew J Byerly; Paul A Nakonezny; A John Rush
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

10.  Opinions of French patients with schizophrenia regarding injectable medication.

Authors:  François Caroli; Philippe Raymondet; Isabelle Izard; Joel Plas; Bérengère Gall; Antonio Delgado
Journal:  Patient Prefer Adherence       Date:  2011-03-21       Impact factor: 2.711

View more
  7 in total

1.  Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.

Authors:  Qian Cai; Charmi Patel; Edward Kim; Nancy Connolly; Ozgur Tunceli; Antoine C El Khoury
Journal:  Adv Ther       Date:  2019-03-08       Impact factor: 3.845

2.  Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.

Authors:  Dee Lin; Philippe Thompson-Leduc; Isabelle Ghelerter; Ha Nguyen; Marie-Hélène Lafeuille; Carmela Benson; Panagiotis Mavros; Patrick Lefebvre
Journal:  CNS Drugs       Date:  2021-04-28       Impact factor: 5.749

3.  Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities.

Authors:  Junli Zhu; Yun Chen; Wei Lu; Qingzhi Huang; Bin Li; Ying Xu; Rui Xi; Lefan Jin
Journal:  Front Public Health       Date:  2021-11-25

4.  Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta-analysis of observational studies.

Authors:  Tiffany Cristarella; Genaro Castillon; Jean-François Nepveu; Yola Moride
Journal:  Pharmacol Res Perspect       Date:  2022-02

5.  Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Shuhei Kudo; Masamichi Ishioka; Yasushi Sato; Kazutoshi Kubo; Norio Yasui-Furukori
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-09       Impact factor: 2.570

6.  Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN).

Authors:  Petru Ifteni; Paula-Simina Petric; Andreea Teodorescu
Journal:  Front Psychiatry       Date:  2021-12-07       Impact factor: 4.157

7.  Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland.

Authors:  Stephan Reymann; Georgios Schoretsanitis; Stephan T Egger; Alexey Mohonko; Matthias Kirschner; Stefan Vetter; Philipp Homan; Erich Seifritz; Achim Burrer
Journal:  J Pers Med       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.